Gene Techno Science Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2019
May 10, 2019 at 11:25 am EDT
Share
Gene Techno Science Co.,Ltd. announced earnings results for the full year ended March 31, 2019. For the full year, the company announced total revenue was JPY 1,021.703 million compared to JPY 1,059.727 million a year ago. Operating loss was JPY 805.167 million compared to JPY 913.499 million a year ago. Net loss was JPY 856.291 million compared to JPY 904.557 million a year ago.
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
KIDSWELL BIO CORPORATION 
